We are taking, Mr. Chair, some steps in the right direction, Mr. Ranking Member in the legislation that we will be working on tomorrow in this committee. And I am hopeful that we are able to specifically tackle insulin prices later this year. But we can't ignore the business practices of the companies that have come before us today. Part of how we tackle drug prices relates to that need to get transparency and that need to take on the aspect of greed. (05:23–05:32)
CLAIM
Asserts hope to address insulin prices later in the year.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
